ClinicalTrials.gg
CompletedNCT02579616Updated Dec 23, 2020Results posted

Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

A Phase 2 interventional study of Lenvatinib in Biliary Tract Cancer, sponsored by Eisai Co., Ltd.. Completed at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-12-23.

Sponsored by Eisai Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing lenvatinib in Biliary Tract Neoplasms — 12 open to participants now, 14 under way, none of them phase 3. lenvatinib · Biliary Tract Neoplasms.

Enrollment
18th of 20
29 · median 46
Started
2015
the only one that year
Phase 2
17 of 20
10 open now
Registered
1st of 20
by date
Lead sponsor
1 of 20
Eisai Co., Ltd.

Among the 20 studies testing lenvatinib in Biliary Tract Neoplasms, this one is the 18th largest by enrollment, is the only one that started in 2015, is one of 17 in phase 2, and was the 1st registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 199 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

12 of the 20 studies testing lenvatinib in Biliary Tract Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing lenvatinib in Biliary Tract Neoplasms, or all of them as a file.
02

Study summary

This is a multicenter, single arm, open-label study in participants with unresectable BTC and disease progression or failure following one prior gemcitabine-based doublet chemotherapy regimen (combination of gemcitabine and cisplatin, or gemcitabine and other platinum agent/fluoropyrimidine agent). This study contains 3 phases: a Pre-treatment phase that will last within 21 days; a Treatment phase that will consist of study treatment cycles and tumor assessment conducted every 6-8 weeks; and a Follow-up phase that will begin immediately after the Off-Treatment Visit and will continue as long as the participant is alive, unless the participant withdraws consent, or until the End of Study.

03

Conditions studied

  • Biliary Tract Cancer

Keywords

  • Lenvatinib
  • E7080
  • Unresectable biliary tract cancer
  • BTC
  • Gemcitabine-based combination chemotherapy
  • Lenvima
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed adenocarcinoma of biliary tract cancer (intrahepatic, extrahepatic cholangiocarcinoma, gall bladder cancer, and ampulla of Vater cancer)
  2. Unresectable (eg, locally advanced or ) BTC
  3. One prior gemcitabine-based doublet chemotherapy (eg, gemcitabine and cisplatin) to unresectable BTC and not treated by any other chemotherapy to BTC

    • Participants who received chemotherapy are eligible if this therapy was completed and recurrent has not been shown for 6 months after the completion of the therapy
  4. meeting the following criteria:

    • At least 1 lesion of ≥ 1.0 cm in the longest diameter for a non-lymph node or ≥ 1.5 cm in the short-axis diameter for a lymph node that is serially measurable according to 1.1 (RECIST1.1) using computerized tomography/magnetic resonance imaging (CT/MRI)
    • Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion
  5. (ECOG) Performance Status of 0-1
  6. Survival expectation of 3 months or longer after beginning of study treatment
  7. Males or females age ≥ 20 years at the time of
  8. All chemotherapy- or radiation-related toxicities must have resolved to Grade 0-1 per (CTCAE v 4.03), except alopecia, infertility, and the adverse events listed in inclusion criteria
  9. Adequately controlled blood pressure (BP) with or without antihypertensive medications (defined as BP ≤ 150/90 mm Hg at Screening and no change in antihypertensive medications within 1 week prior to the first dose of study drug)
  10. Participants with adequate function of major organs and blood coagulation:

    • (ANC) ≥ 1500/mm\^3 ( ≥ 1.5×103/μl)
    • ≥ 100,000/mm3 ( ≥ 100×10\^9/L)
    • ≥ 9.0 g/dL
    • ≤ 2.0 mg/dL except for unconjugated hyperbilirubinemia or Gilbert's syndrome
    • Alkaline phosphatase (ALP), (AST), and alanine aminotransferase (ALT) ≤ 3.0 × (ULN) ( ≤ 5.0 × ULN for participants with the liver metastasis)
    • ≥ 40 mL/min per the Cockcroft and Gault formula
    • -International Normalized Ratio (PT-INR) ≤ 1.5
  11. Participants must voluntarily agree to provide written informed consent
  12. Participants must be willing and able to comply with all aspects of the protocol

Exclusion criteria

Exclusion Criteria:

  1. Any anti-cancer treatment (except BSC) within 21 days prior to the first dose of study drug
  2. Major surgery (any surgical procedure that involves anesthesia or respiratory assistance) within 21 days prior to the first dose of study drug or scheduled surgery during the study (except for bile duct drainage)
  3. Ascites of moderate, severe, or requiring drainage
  4. Proteinuria of ≥ 2+ on dipstick testing (Grade ≤ 1 confirmed by quantitative assessment is eligible)
  5. Gastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of study drug
  6. congestive heart failure of class II or above, unstable angina, myocardial infarction, or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past 6 months from the first dose of study drug
  7. A prolonged /QTc interval (QTcF > 480 ms)
  8. Known to be (HIV) positive
  9. Active infection requiring systemic treatment
  10. Bleeding or thrombotic disorders or chronic systemic use of anticoagulants requiring therapeutic monitoring, eg, warfarin or similar agents (treatment with low molecular weight heparin is permitted)
  11. Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5 teaspoon) within 21 days prior to the first dose of study drug
  12. Active (except for BTC or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, carcinoma in-situ of the cervix, or early stage gastric/colorectal cancer) within the past 24 months prior to the first dose of study drug
  13. Diagnosed with meningeal carcinomatosis
  14. Participants with brain or subdural are not eligible, unless they have completed local therapy and have discontinued the use of for this indication for at least 28 days prior to the first dose of study drug. Any signs (eg, radiologic) or symptoms of must be stable for at least 28 days prior to the first dose of study drug.
  15. Known intolerance to the study drug or any of the
  16. History of drug or alcohol dependency or abuse within the last 24 months prior to the first dose of study drug
  17. Any medical or other condition that in the opinion of the investigator(s) would preclude the participant's participation in a clinical study
  18. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive human chorionic gonadotropin [hCG or B-hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 3 days before the first dose of study drug.
  19. For either males unless undergoing a successful vasectomy (confirmed azoospermia) or females of , the participant and his/her partner do not agree to use a medically appropriate method of throughout the entire study period

    • the use of condom, contraceptive sponge, contraceptive foam, contraceptive jelly, diaphragm, or intrauterine device, otherwise using oral contraceptive (percutaneous or transvaginal also allowed) for at least 28 days before the first dose of study drug
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    24 mg Lenvatinib

    Participants with unresectable BTC and disease progression or failure following one prior gemcitabine-based doublet chemotherapy regimen (combination of gemcitabine and cisplatin, or gemcitabine and other platinum agent/fluoropyrimidine agent).

    Drug: Lenvatinib

Interventions

  • Lenvatinib will be administered orally once daily in 28-day cycles. Participants will be treated until disease progression, unacceptable toxicity, withdrawal of consent, participant's choice, etc.

    Also known as: E7080, Lenvima, Lenvatinib Mesylate

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was assessed by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. ORR was defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR). Confirmation of CR or PR was performed at least 28 days following the initial achievement of the response.

    Time frame: From the date of first dose of study drug to the date of last documentation of disease progression or date of death from any cause, whichever occurred first (up to approximately 1 year 1 month)

Secondary outcomes

  1. Progression-free Survival (PFS) Rate at 12 Weeks

    PFS was assessed by the investigator based on RECIST 1.1. PFS was defined as the time from the date of first dose to the date of last documentation of disease progression or death from any cause, whichever occurred first. PFS rate was cumulative probability for event-free participants at 12 weeks. PFS rate at 12 weeks was calculated using Kaplan-Meier method.

    Time frame: From the date of first dose to the date of last documentation of disease progression or death from any cause, whichever occurred first (up to Week 12)

  2. Progression-free Survival (PFS)

    PFS was assessed by the investigator based on RECIST 1.1. PFS was defined as the time from the date of first dose to the date of last documentation of disease progression or date of death from any cause, whichever occurred first. For participants who did not have an event, PFS were censored. PFS was calculated using Kaplan-Meier method.

    Time frame: From the date of first dose of study drug to the date of last documentation of disease progression or date of death from any cause, whichever occurred first (up to approximately 3 years 4 months)

  3. Overall Survival (OS)

    OS was defined as the time from the date of first dose to the date of death from any cause. For the participants who were alive or unknown, OS was censored on the last date participant was known to be event-free or date of data-cut-off. OS was calculated using the Kaplan-Meier method.

    Time frame: From the date of first dose of study drug to the date of death from any cause (up to approximately 3 years 4 months)

  4. Disease Control Rate (DCR)

    DCR was assessed by the investigator based on RECIST 1.1. DCR was defined as the percentage of participants whose BOR was CR, PR or SD.

    Time frame: From the date of first dose of study drug to the date of last documentation of disease progression or date of death from any cause, whichever occurred first (up to approximately 3 years 4 months)

  5. Clinical Benefit Rate (CBR)

    CBR was assessed by the investigator based on RECIST 1.1.CBR was defined as percentage of participants with BOR of CR, PR or durable SD. Durable SD: Durable SD: duration of SD greater than or equal to (\>=23) weeks.

    Time frame: From the date of first dose of study drug to the date of the last documentation of disease progression or death from any cause, whichever occurred first (up to approximately 3 years 4 months)

  6. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From signing of informed consent form to 30 days after the decision to discontinue study treatment or 30 days after last dose of study drug, whichever comes later (up to approximately 3 years 4 months)

  7. Plasma Concentrations of Lenvatinib

    Time frame: Cycle 1 Day 1: 0.5-2 hours post dose (Cycle length is 28 days)

07

Results

Posted Dec 23, 2020

Participant flow

Participants took part in the study at 7 investigative sites in Japan from 23 Oct 2015 to 27 Feb 2019.

Participant flow — Overall Study
MilestoneLenvatinib 24 mg
Started29
Treated26
Completed26
Not completed3
Withdrew: Participants did not receive treatment3

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was assessed by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. ORR was defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR). Confirmation of CR or PR was performed at least 28 days following the initial achievement of the response.

Time frame:
From the date of first dose of study drug to the date of last documentation of disease progression or date of death from any cause, whichever occurred first (up to approximately 1 year 1 month)
Reported as:
Number · percentage of participant
Objective Response Rate (ORR)
percentage of participantLenvatinib 24 mg
Objective Response Rate (ORR)11.5 (2.4 to 30.2)
SecondaryProgression-free Survival (PFS) Rate at 12 Weeks

PFS was assessed by the investigator based on RECIST 1.1. PFS was defined as the time from the date of first dose to the date of last documentation of disease progression or death from any cause, whichever occurred first. PFS rate was cumulative probability for event-free participants at 12 weeks. PFS rate at 12 weeks was calculated using Kaplan-Meier method.

Time frame:
From the date of first dose to the date of last documentation of disease progression or death from any cause, whichever occurred first (up to Week 12)
Reported as:
Number · percentage of participant
Progression-free Survival (PFS) Rate at 12 Weeks
percentage of participantLenvatinib 24 mg
Progression-free Survival (PFS) Rate at 12 Weeks72.2 (50.4 to 85.7)
SecondaryProgression-free Survival (PFS)

PFS was assessed by the investigator based on RECIST 1.1. PFS was defined as the time from the date of first dose to the date of last documentation of disease progression or date of death from any cause, whichever occurred first. For participants who did not have an event, PFS were censored. PFS was calculated using Kaplan-Meier method.

Time frame:
From the date of first dose of study drug to the date of last documentation of disease progression or date of death from any cause, whichever occurred first (up to approximately 3 years 4 months)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsLenvatinib 24 mg
Progression-free Survival (PFS)3.19 (2.79 to 7.23)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of first dose to the date of death from any cause. For the participants who were alive or unknown, OS was censored on the last date participant was known to be event-free or date of data-cut-off. OS was calculated using the Kaplan-Meier method.

Time frame:
From the date of first dose of study drug to the date of death from any cause (up to approximately 3 years 4 months)
Reported as:
Median · months
Overall Survival (OS)
monthsLenvatinib 24 mg
Overall Survival (OS)7.35 (4.50 to 11.27)
SecondaryDisease Control Rate (DCR)

DCR was assessed by the investigator based on RECIST 1.1. DCR was defined as the percentage of participants whose BOR was CR, PR or SD.

Time frame:
From the date of first dose of study drug to the date of last documentation of disease progression or date of death from any cause, whichever occurred first (up to approximately 3 years 4 months)
Reported as:
Number · percentage of participant
Disease Control Rate (DCR)
percentage of participantLenvatinib 24 mg
Disease Control Rate (DCR)84.6 (65.1 to 95.6)
SecondaryClinical Benefit Rate (CBR)

CBR was assessed by the investigator based on RECIST 1.1.CBR was defined as percentage of participants with BOR of CR, PR or durable SD. Durable SD: Durable SD: duration of SD greater than or equal to (\>=23) weeks.

Time frame:
From the date of first dose of study drug to the date of the last documentation of disease progression or death from any cause, whichever occurred first (up to approximately 3 years 4 months)
Reported as:
Number · percentage of participant
Clinical Benefit Rate (CBR)
percentage of participantLenvatinib 24 mg
Clinical Benefit Rate (CBR)38.5 (20.2 to 59.4)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
From signing of informed consent form to 30 days after the decision to discontinue study treatment or 30 days after last dose of study drug, whichever comes later (up to approximately 3 years 4 months)
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsLenvatinib 24 mg
TEAEs26
SAEs18
SecondaryPlasma Concentrations of Lenvatinib
Time frame:
Cycle 1 Day 1: 0.5-2 hours post dose (Cycle length is 28 days)
Reported as:
Median · nanogram per milliliter (ng/mL)
Plasma Concentrations of Lenvatinib
nanogram per milliliter (ng/mL)Lenvatinib 24 mg
Plasma Concentrations of Lenvatinib3.90 (NA to 782)

Adverse events

Collected over From signing of informed consent form to 30 days after the decision to discontinue study treatment or 30 days after last dose of study drug, whichever comes later (up to approximately 3 years 4 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib 24 mg17/26 (65.4%)18/26 (69.2%)26/26 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventLenvatinib 24 mg
CholangitisHepatobiliary disorders4/26
Bile duct obstructionHepatobiliary disorders2/26
Decreased appetiteMetabolism and nutrition disorders2/26
Abdominal distensionGastrointestinal disorders1/26
Gastrointestinal haemorrhageGastrointestinal disorders1/26
Gastrointestinal obstructionGastrointestinal disorders1/26
Gastrointestinal perforationGastrointestinal disorders1/26
Bile duct stenosisHepatobiliary disorders1/26
Cholecystitis 1Hepatobiliary disorders1/26
HaemobiliaHepatobiliary disorders1/26
Most frequent other events
Showing 10 of 106
Most frequent other events
EventLenvatinib 24 mg
HypertensionVascular disorders22/26
ProteinuriaRenal and urinary disorders16/26
DysphoniaRespiratory, thoracic and mediastinal disorders16/26
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders15/26
ThrombocytopeniaBlood and lymphatic system disorders14/26
Decreased appetiteMetabolism and nutrition disorders14/26
FatigueGeneral disorders13/26
HypothyroidismEndocrine disorders12/26
Oedema peripheralGeneral disorders9/26
ConstipationGastrointestinal disorders8/26

Baseline characteristics

The full analysis set (FAS) included the group of participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Lenvatinib 24 mg
Mean62.1 ± 9.48
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib 24 mg
Female11
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenvatinib 24 mg
Hispanic or Latino0
Not Hispanic or Latino26
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lenvatinib 24 mg
American Indian or Alaska Native0
Asian26
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

7 sites
  • Nagoya, Aichi, Japan
  • Kashiwa, Chiba, Japan
  • Yokohama, Kanagawa, Japan
  • Ina-machi, Saitama, Japan
  • Chuo-ku, Tokyo, Japan
  • Koto-ku, Tokyo, Japan
  • Mitaka, Tokyo, Japan
09

References and documents

Publications

  • Ueno M, Ikeda M, Sasaki T, Nagashima F, Mizuno N, Shimizu S, Ikezawa H, Hayata N, Nakajima R, Morizane C. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer. 2020 Nov 16;20(1):1105. doi: 10.1186/s12885-020-07365-4. PubMed 33198671 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Nov 2016, 12 months.

Results were first posted in Dec 2020, 4 years 1 month after primary completion.

Of 129 phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 68. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2015
First posted
Oct 19, 2015
StartActual
Oct 23, 2015
Primary completionActual
Nov 22, 2016
CompletionActual
Feb 27, 2019
Results first posted
Dec 23, 2020
Last update
Dec 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02579616
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Oct 19, 2015
Start date
Oct 23, 2015
Primary completion
Nov 22, 2016
Completion
Feb 27, 2019
Results posted
Dec 23, 2020
Last update
Dec 23, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion